A National Bioeconomy Manufacturing and Innovation Initiative
Summary
The COVID-19 pandemic has devastated the world. In the same year, record fires, hurricanes, and weather wreaked havoc on the United States. These disasters have had devastating economic effects on American lives. To combat COVID-19, foster economic recovery, and address climate change, the United States should implement a National Bioeconomy Manufacturing and Innovation Initiative. The U.S. bioeconomy is composed of healthcare, agriculture, and life-science companies and contributes an estimated 2% of the U.S. GDP. This figure is expected to rise in the coming decade. The bioeconomy also contributes to addressing climate change by reducing U.S. dependence on petroleum-based products and creates American jobs through a growing biomanufacturing sector. Biomanufacturing is the production of products via biological and biosynthetic mechanisms, such as fermentation-based production of industrial ethanol. To fully realize the potential of the bioeconomy, the United States must invest in cross-cutting research and development (R&D) across the areas of healthcare, food & agriculture, energy, environment, and industrial applications. The pillars of this “National Bioeconomy Manufacturing and Innovation Initiative” should focus on (1) cutting-edge R&D, (2) development of fundamental and publicly available tools, and (3) biomanufacturing. The initiative should be coordinated out of the Executive Office of the President via a National Bioeconomy Coordination Office. The initiative should be supported by senior leadership positions at each federal agency with equities in the U.S. bioeconomy, as well as by appropriated funding.
To better understand what might drive the way we live, learn, and work in 2050, we’re asking the community to share their expertise and thoughts about how key factors like research and development infrastructure and automation will shape the trajectory of the ecosystem.
Recognizing the power of the national transportation infrastructure expert community and its distributed expertise, ARPA-I took a different route that would instead bring the full collective brainpower to bear around appropriately ambitious ideas.
NIH needs to seriously invest in both the infrastructure and funding to undertake rigorous nutrition clinical trials, so that we can rapidly improve food and make progress on obesity.
Modernizing ClinicalTrials.gov will empower patients, oncologists, and others to better understand what trials are available, where they are available, and their up-to-date eligibility criteria, using standardized search categories to make them more easily discoverable.